Dust, smoke, and chemicals in the air cause about 1%-2% of lung cancers. Researchers suspect that polluted air can cause ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Johnson & Johnson’s (J&J) Lazcluze (lazertinib) has been approved by the Medicines and Healthcare products Regulatory Agency ...

(the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...